id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-E-0164-0008,FDA,FDA-2009-E-0164,Notice of Final Determination - Letter,Other,Letter(s),2012-01-12T05:00:00Z,2012,1,2012-01-12T05:00:00Z,,2012-01-12T15:24:44Z,,0,0,0900006480f93c4f
FDA-2009-E-0164-0007,FDA,FDA-2009-E-0164,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2011-02-23T05:00:00Z,2011,2,2011-02-23T05:00:00Z,,2011-02-23T16:56:47Z,,0,0,0900006480bf6500
FDA-2009-E-0164-0006,FDA,FDA-2009-E-0164,Determination of Regulatory Review Period for Purposes of Patent Extension: MOZOBIL,Notice,N-Notice,2010-04-09T04:00:00Z,2010,4,2010-04-09T04:00:00Z,2010-06-09T03:59:59Z,2010-04-09T15:47:15Z,2010-08172,0,0,0900006480ad3f87
FDA-2009-E-0164-0005,FDA,FDA-2009-E-0164,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2010-03-24T04:00:00Z,2010,3,2010-03-24T04:00:00Z,,2013-07-27T23:13:12Z,,0,0,0900006480ac78d7
FDA-2009-E-0164-0004,FDA,FDA-2009-E-0164,U.S. Patent and Trademark Office to FDA/CDER - Letter,Other,LET-Letter,2009-12-08T05:00:00Z,2009,12,2009-12-08T05:00:00Z,,2013-07-27T23:01:45Z,,0,0,0900006480a667cf
FDA-2009-E-0164-0003,FDA,FDA-2009-E-0164,FDA/CDER to the U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2009-10-01T04:00:00Z,2009,10,2009-10-01T04:00:00Z,,2009-10-01T18:56:47Z,,0,0,0900006480a366cc
FDA-2009-E-0164-0002,FDA,FDA-2009-E-0164,Genzyme Corporation - Patent Term Extension Application,Other,APP-Application,2009-03-27T04:00:00Z,2009,3,2009-03-27T04:00:00Z,,2009-03-27T19:32:45Z,,0,0,0900006480933a98
FDA-2009-E-0164-0001,FDA,FDA-2009-E-0164,U.S. Patent and Trademark Office to FDA/CDER - Letter,Other,LET-Letter,2009-03-27T04:00:00Z,2009,3,2009-03-27T04:00:00Z,,2009-03-27T19:32:43Z,,0,0,0900006480933a81